Fluorinated butyric acids and their derivatives as inhibitors of matrix
metalloproteinases
    5.
    发明授权
    Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases 失效
    氟化丁酸及其衍生物作为基质金属蛋白酶的抑制剂

    公开(公告)号:US06037361A

    公开(公告)日:2000-03-14

    申请号:US36751

    申请日:1998-03-09

    摘要: Fluorinated butyric acid compounds and derivatives are described as well as acid methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1, and also collagenase, matrilysin, and MMP-13, and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

    摘要翻译: 描述了氟化丁酸化合物和衍生物以及用于制备的酸法和其药物组合物,其可用作基质金属蛋白酶抑制剂,特别是明胶酶A(72kD明胶酶)和基质溶素-1,以及胶原酶,基质溶素, 和MMP-13,用于治疗多发性硬化,动脉粥样硬化斑块破裂,主动脉瘤,心力衰竭,再狭窄,牙周病,角膜溃疡,烧伤治疗,褥疮溃疡,伤口愈合,癌症,炎症,疼痛,关节炎或 依赖于白细胞或其他活化迁移细胞的组织侵袭的其它自身免疫性或炎性病症,急性和慢性神经变性疾病,包括中风,头部创伤,脊髓损伤,阿尔茨海默氏病,肌萎缩性侧索硬化,脑淀粉样血管病,艾滋病,帕金森病,亨廷顿舞蹈病 ,朊病毒疾病,重症肌无力和杜氏肌营养不良症。

    N-aminoalkylfluorenecarboxamides
    6.
    发明授权
    N-aminoalkylfluorenecarboxamides 失效
    N-氨基烷基芴甲酰胺

    公开(公告)号:US6015900A

    公开(公告)日:2000-01-18

    申请号:US43022

    申请日:1998-11-23

    申请人: Jun Yuan Xi Chen

    发明人: Jun Yuan Xi Chen

    摘要: Disclosed are compounds of formula (I) or the pharmaceutically acceptable salts thereof wherein: ##STR1## G represents a group of the formula (a), (b) or (c) where R.sub.a and R.sub.b represent hydrogen, or organic or inorganic substituents; A is an optionally substituted alkylene; R.sub.1, R.sub.2, R.sub.3, R.sub.4 represent organic or inorganic substituents; R.sub.5 is hydrogen or lower alkyl; R.sub.6 and R.sub.7 independently represent hydrogen, lower alkyl; or together form a ring of 5-8 members; Z is nitrogen or carbon; and W is optionally susbtituted aryl or heteroaryl. Compounds of the present invention demonstrate high affinity and selectivity in binding to the D.sub.3 receptor subtype.

    摘要翻译: PCT No.PCT / US96 / 14650 Sec。 371日期:1998年11月23日 102(e)1998年11月23日日期PCT 1996年9月12日PCT公布。 出版物WO97 / 10229 日期1997年3月20日公开是式(I)化合物或其药学上可接受的盐,其中:G表示式(a),(b)或(c)的基团,其中R a和R b表示氢,或有机或无机 取代基; A是任选取代的亚烷基; R1,R2,R3,R4代表有机或无机取代基; R5是氢或低级烷基; R6和R7独立地表示氢,低级烷基; 或一起组成5-8名成员的戒指; Z是氮或碳; 并且W是任选的取代的芳基或杂芳基。 本发明化合物在与D3受体亚型结合中表现出高亲和力和选择性。

    Gel-forming polypeptide derivatives
    7.
    发明授权
    Gel-forming polypeptide derivatives 失效
    凝胶形成多肽衍生物

    公开(公告)号:US5955434A

    公开(公告)日:1999-09-21

    申请号:US693215

    申请日:1996-08-09

    摘要: The invention relates to N-terminal Fmoc-protected peptide combinations that form gels in water and diverse organic solvents, and whose representative overall formulas are: (I), where R.sup.1 is CH.sub.3, CH.sub.2 --CH(CH.sub.3).sub.3, CH(CH.sub.3)CH.sub.2 CH.sub.3, R.sup.2 is H, CH.sub.3, CH.sub.2 OH, (CH.sub.2).sub.n --COOH, (CH.sub.2)4--NH--CO--OCH.sub.2 C.sub.6 H.sub.5, R.sup.3 is dipeptide remainder, m is 0 or 1 and, n is 1 or 2; or (II), where R1 is CH.sub.3, CH.sub.2 --CH(CH.sub.3)2, or CH(CH.sub.3)CH.sub.2 CH3, R2 is CH2--CH(CH3)2, R3 is H, CH.sub.3, CH.sub.2 OH, (CH.sub.2).sub.n --COOH, or (CH.sub.2)4--NH--CO--OCH.sub.2 C.sub.6 H.sub.5, R.sub.4 is tripeptide remainder, m is 0 or 1 and, n is 1 or 2. These types of peptides form gels in aqueous solutions and are biologically compatible and may be useful for drug delivery, antigen delivery and may be useful as food additives to retard spoilage and act as fillers.

    摘要翻译: PCT No.PCT / US95 / 01890 Sec。 371日期1997年1月24日 102(e)日期1997年1月24日PCT提交1995年2月9日PCT公布。 出版物WO95 / 21622 日期:1995年8月17日本发明涉及在水和多种有机溶剂中形成凝胶的N-末端Fmoc保护的肽组合,其代表性总体式为:(I),其中R 1为CH 3,CH 2 -CH(CH 3)3 ,CH(CH3)CH2CH3,R2是H,CH3,CH2OH,(CH2)n-COOH,(CH2)4-NH-CO-OCH2C6H5,R3是二肽余数,m是0或1,n是1或2 ; 或(II),其中R1是CH3,CH2-CH(CH3)2或CH(CH3)CH2CH3,R2是CH2-CH(CH3)2,R3是H,CH3,CH2OH,(CH2)n-COOH, 或(CH 2)4 -NH-CO-OCH 2 C 6 H 5,R 4是三肽残基,m是0或1,并且n是1或2.这些类型的肽在水溶液中形成凝胶并且在生物学上相容并且可用于药物递送 ,抗原递送,并且可用作食品添加剂以延缓腐败并充当填料。